

POSTER PRESENTATION

Open Access

Bioengineering cytotoxic T cells to target opportunistic fungal infection

Pappanaicken Kumaresan^{1*}, Pallavi R Manuri¹, Nathaniel Albert², Brian Rabinovich¹, Simon Olivares¹, Sourindra N Maiti¹, Helen Huls¹, Dean A Lee¹, Dimitrios Kontoyiannis², Laurence J Cooper¹

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Clinical-grade T cells are genetically modified *ex vivo* to express chimeric antigen receptors (CARs) to redirect their specificity to target tumor-associated antigens *in vivo*. We have developed gene therapy approach to render T cells specific for invasive fungal infections (IFI) due to *Aspergillus*. We adapted the pattern-recognition receptor Dectin-1 to activate T cells via chimeric CD28 and CD3-zeta (designated D-CAR) upon binding with carbohydrate cell wall in *Aspergillus* germlings. T cells genetically modified with Sleeping Beauty system to stably express D-CAR were selectively propagated on artificial antigen presenting cells using an approach that is approved by FDA to develop CAR T cells for clinical trials. The D-CAR+ T cells exhibited specificity for beta-1,3-gucan and damaged and thus inhibited hyphal growth of *Aspergillus*. Treatment of D-CAR+ T cells with steroids did not compromise anti-fungal activity. Thus, we report a clinically-appealing strategy to transfer innate immunity for mycology to cytotoxic T cells.

Authors' details

¹Department of Pediatrics, MDACC, Houston, TX, USA. ²Department of Infectious Disease, MDACC, Houston, TX, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P4

Cite this article as: Kumaresan et al.: Bioengineering cytotoxic T cells to target opportunistic fungal infection. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):P4.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Department of Pediatrics, MDACC, Houston, TX, USA
Full list of author information is available at the end of the article